For the quarter ending 2025-09-30, ARQT made $99,219K in revenue. $7,383K in net income. Net profit margin of 7.44%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 99,219 | 81,504 | 65,846 | 71,360 |
| Cost of sales | 8,685 | 7,492 | 8,830 | 6,905 |
| Research and development | 19,604 | 19,453 | 17,543 | 14,480 |
| Selling, general and administrative | 62,404 | 69,170 | 64,002 | 57,607 |
| Total operating expenses | 90,693 | 96,115 | 90,375 | 78,992 |
| Income (loss) from operations | 8,526 | -14,611 | -24,529 | -7,632 |
| Other income, net | 2,035 | 2,096 | 2,730 | 2,718 |
| Interest expense | 3,071 | 3,029 | 2,982 | 7,480 |
| Income (loss) before income taxes | 7,490 | -15,544 | -24,781 | -10,465 |
| Provision for income taxes | 80 | 342 | 279 | 323 |
| Net income (loss) | 7,410 | -15,886 | -25,060 | -10,788 |
| Unrealized gain (loss) on marketable securities | 68 | -95 | -137 | -309 |
| Foreign currency translation adjustment | -95 | 200 | 4 | -231 |
| Total other comprehensive income (loss) | -27 | 105 | -133 | -540 |
| Comprehensive income (loss) | 7,383 | -15,781 | -25,193 | -11,328 |
| Basic (in shares) | 127,623,000 | 126,997,000 | 126,036,862 | -237,874,058 |
| Basic (in usd per share) | 0.06 | -0.13 | -0.2 | -0.09 |
| Diluted (in shares) | 132,885,000 | 126,997,000 | 126,036,862 | -237,874,058 |
| Diluted (in usd per share) | 0.06 | -0.13 | -0.2 | -0.09 |
Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT)